Latency intervals according to primary diagnosis and cytogenetic features in patients with t-MDS/t-AML
Primary diagnosis . | No. patients . | Abnormality 5 . | Abnormality 7 . | Abnormalities 5 and 7 . | Balanced rearrangement . | Other abnormalities . | Normal . |
|---|---|---|---|---|---|---|---|
| No malignancy | 18 | — | 157 | — | — | — | — |
| Hematologic malignancy | 167 | 73 | 65 | 63 | 30 | 63 | 41 |
| Hodgkin disease | 75 | 58 | 65 | 68 | — | 66 | — |
| Non-Hodgkin lymphoma | 69 | 106 | 76 | 59 | — | 60 | — |
| Myeloma | 22 | 72 | 50 | — | — | — | — |
| Other | 1 | — | — | — | — | — | — |
| Solid tumor | 109 | 48 | 56 | 77 | 28 | 71 | 88 |
| Breast | 30 | 69 | 66 | — | 25 | — | — |
| Ovary | 12 | — | — | — | — | — | — |
| Prostate | 12 | — | — | — | — | — | — |
| Lung | 9 | — | — | — | — | — | — |
| Cervix | 7 | — | — | — | — | — | — |
| Other | 39 | 51 | 52 | 105 | 31 | — | 78 |
| Median latency, mo | NA | 64 | 66 | 65 | 28* | 68 | 69 |
| IQR, mo | NA | 39-114 | 44-115 | 45-107 | 18-49* | 38-97 | 34-115 |
| Range, mo | NA | 13-396 | 3-626 | 10-276 | 9-216 | 12-548 | 12-440 |
| Total patients, n | 294 | 60 | 84 | 60 | 31 | 36 | 23 |
Primary diagnosis . | No. patients . | Abnormality 5 . | Abnormality 7 . | Abnormalities 5 and 7 . | Balanced rearrangement . | Other abnormalities . | Normal . |
|---|---|---|---|---|---|---|---|
| No malignancy | 18 | — | 157 | — | — | — | — |
| Hematologic malignancy | 167 | 73 | 65 | 63 | 30 | 63 | 41 |
| Hodgkin disease | 75 | 58 | 65 | 68 | — | 66 | — |
| Non-Hodgkin lymphoma | 69 | 106 | 76 | 59 | — | 60 | — |
| Myeloma | 22 | 72 | 50 | — | — | — | — |
| Other | 1 | — | — | — | — | — | — |
| Solid tumor | 109 | 48 | 56 | 77 | 28 | 71 | 88 |
| Breast | 30 | 69 | 66 | — | 25 | — | — |
| Ovary | 12 | — | — | — | — | — | — |
| Prostate | 12 | — | — | — | — | — | — |
| Lung | 9 | — | — | — | — | — | — |
| Cervix | 7 | — | — | — | — | — | — |
| Other | 39 | 51 | 52 | 105 | 31 | — | 78 |
| Median latency, mo | NA | 64 | 66 | 65 | 28* | 68 | 69 |
| IQR, mo | NA | 39-114 | 44-115 | 45-107 | 18-49* | 38-97 | 34-115 |
| Range, mo | NA | 13-396 | 3-626 | 10-276 | 9-216 | 12-548 | 12-440 |
| Total patients, n | 294 | 60 | 84 | 60 | 31 | 36 | 23 |
NA indicates not applicable;—, subgroups with fewer than 5 subjects (medians were not computed for these patients).
Patients with balanced rearrangements had significantly shorter latency periods than all other cytogenetic groups (P = .0003).